Patent Application announced 11 July 02.
BPI does everything, too bad it can't get approved for just one thing. <g>
United States Patent Application
20020090368
Kind Code
A1
Little, Roger G. II
July 11, 2002
Therapeutic uses of bactericidal/permeability increasing (BPI) protein products
Abstract
The present invention provides therapeutic methods for treatment of conditions including the neutralization of the anti-coagulant activity of heparin, inhibition of
angiogenesis, tumor and endothelial cell proliferation, and treatment of chronic inflammatory diseases by administration of bactericidal/permeability-increasing
(BPI) protein products.
Inventors:
Little, Roger G. II; (Benicia, CA)
Correspondence
Name and
Address:
Janet M. McNicholas, Ph.D.
McAndrews, Held & Malloy, Ltd.
34th Floor
500 W. Madison Street
Chicago
IL
60661
US
Assignee Name
and Adress:
XOMA Corporation
Serial No.:
942021
Series Code:
09
Filed:
August 27, 2001
U.S. Current Class:
424/94.61
U.S. Class at Publication:
424/94.61
Intern'l Class:
A61K 038/47
Claims
1. A method for neutralizing the anti-coagulant effect of heparin comprising administering to a subject an effective amount of a heparin binding BPI protein
product.
2. A method of inhibiting angiogenesis comprising administering to a subject an amount of a BPI protein product effective to inhibit angiogenesis.
3. A method for neutralizing the anti-coagulant effect of heparin in a fluid sample comprising contacting said sample with an effective amount of heparin
binding BPI protein product.
4. The method of claim 2 wherein the angiogenesis inhibited is associated with ocular retinopathy.
5. A method for inhibiting endothelial cell proliferation comprising administering to a subject an amount of a BPI protein product effective to inhibit
proliferation.
6. A method of treating endometriosis comprising administering an amount of BPI to the endometrium effective to inhibit endothelial cell proliferation.
7. A method for contraception comprising administering to a subject an amount of a BPI protein product to the uterine lining effective to prevent endothelial cell
proliferation associated with implantation of a fertilized ovum.
8. A method for inhibiting malignant tumor cell proliferation comprising administering to a subject an amount of a BPI protein product effective to inhibit
proliferation.
9. The method of claim 8 wherein the malignant tumor is Kaposi's sarcoma.
10. A method for treating a chronic inflammatory disease state comprising administering to a subject an amount of a BPI protein product effective to reduce
inflammation.
11. The method of claim 10 wherein the chronic inflammatory disease is arthritis.
12. The method of claim 11 wherein the arthritic inflammatory disease state is rheumatoid arthritis.
13. The method of claim 11 wherein the arthritic inflammatory disease state treated is reactive arthritis.
14. The method of claims 1, 2, 5, 6, 7, 8 and 10 wherein the BPI protein product is a 23-25 kD amino-terminal fragment of bactericidal/permeabilit- y-increasing
protein.
15. A method of inhibiting antiogenesis comprising administering to a subject an amount of a BPI protein product effective to inhibit angiogenesis.
16. The method of claim 15 wherein the angiogenesis inhibited is associated with ocular retinopathy.
17. A method for inhibiting endothelial cell proliferation comprising administering to a subject an amount of a bactericidal/permeability increasing (BPI) protein
product effective to inhibit proliferation of endothelial cells.
18. A method of treating endometriosis comprising administering an amount of BPI to the endometrium effective to inhibit endothelial cell proliferation.
19. A method for contraception comprising administering to a subject an amount of a BPI protein product to the uterine lining effective to provent endothelial
cell proliferation associated with implantation of a fertilized ovum.
20. A method of inhibiting malignant tumor cell proliferation comprising administering to a subject an amount of a BPI protein product effective to inhibit
proliferation.
21. The method of claim 20 wherein the malignant tumor is Kaposi's sarcoma.
22. The method of claim 17 wherein the BPI protein product is an approximately 21 to 25 kD amino-terminal fragment of BPI protein. |
